admin

February 22, 2022

Melbourne, Australia;
22 February 2022 – Research Data Which Covers OBM’s OBM-1701 for the Treatment of wet-AMD Has Been Published on a Prominent Peer-reviewed Journal

Oculus Biomed Limited (“OBM”) is pleased to announce that the research data which covers OBM’s OBM-1701, its leading drug candidate for the treatment of wet-AMD, has […]
October 5, 2021

Melbourne, Australia;
05 October 2021 – OBM Enters R&D Agreement with Centre for Eye Research Australia (“CERA”)

Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered an Agreement with Centre for Eye Research Australia (“CERA”), in Melbourne, Victoria State, Australia. […]
June 11, 2021

Melbourne, Australia;
11 June 2021 – Key Chinese Patent covering OBM-1701 Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the Chinese Patent which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type […]
June 2, 2021

Melbourne, Australia;
2 June 2021 – Key EU Patent covering OBM-1701 Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the European patent application which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type age-related macular […]
May 3, 2021

Melbourne, Australia;
7 April 2021 – Key Chinese Patent Covering OBM-1701 Allowed

Oculus Biomed Limited (“OBM”) is pleased to announce the application of the Chinese Patent which covers its OBM-1701 has been allowed. The term of the Chinese […]
January 8, 2021

Melbourne, Australia;
8 January 2021 – Key Chinese Patent covering OBM-17xx Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the Chinese Patent which covers its OBM- 17xx. The term of the Chinese patent extend […]
July 1, 2020

Melbourne, Australia;
1 July 2020- OBM Enters R&D Agreement with Mackay Memorial Hospital (“MMH”)

Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered an Agreement with Mackay Memorial Hospital (“MMH”), in Taipei, Taiwan. Established on 26 December […]
May 15, 2020

Melbourne, Australia;
15 May 2020 – OBM Terminates Acquisition Discussion with Lanka Graphite Limited

Oculus Biomed Limited (“OBM”) announces that it had requested to terminate the acquisition discussion with Lanka Graphite Limited (“LGR”) (ASX:LGR), effective immediately. OBM has no further […]
February 18, 2020

Melbourne, Australia;
18 February 2020 – OBM Signs Non-Binding Heads of Agreement with Lanka Graphite Limited

Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered into a non-binding Heads of Agreement (“HOA”) with Lanka Graphite Limited (“LGR”) (ASX: LGR). […]